Treatment of metastatic colorectal cancer: focus on panitumumab

被引：18

作者：

Tay, Rebecca Y. ^{[1
]}

Wong, Rachel ^{[1
,2
,3
]}

Hawkes, Eliza A. ^{[1
,3
,4
]}

机构：

[1] Eastern Hlth, Dept Med Oncol, Box Hill, Vic, Australia

[2] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia

[3] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia

[4] Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Dept Oncol, Level 4, Heidelberg, Vic 3084, Australia

来源：

CANCER MANAGEMENT AND RESEARCH | 2015年 / 7卷

关键词：

panitumumab; metastatic colorectal cancer; KRAS; RAS; EGFR; monoclonal antibody; WILD-TYPE KRAS; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; PLUS IRINOTECAN; CLINICAL-TRIAL; RAS MUTATIONS; CETUXIMAB; FLUOROURACIL;

D O I：

10.2147/CMAR.S71821

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

引用

下载

页码：189 / 198

页数：10

共 50 条

[11] Spotlight on Panitumumab in Metastatic Colorectal Cancer
Gillian M. Keating
BioDrugs, 2010, 24 : 275 - 278
[12] Panitumumab (Vectibix) for metastatic colorectal cancer
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1259): : 35 - 36
[13] Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
Bouche, Olivier
Ben Abdelghani, Meher
Labourey, Jean-Luc
Triby, Simon
Bensadoun, Rene-Jean
Jouary, Thomas
Des Guetz, Gaetan
WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (29) : 4007 - 4018
[14] Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer
Addeo, Raffaele
Caraglia, Michele
Cerbone, Domenico
Frega, Nicola
Cimmino, Gaetano
Abbruzzese, Alberto
Del Prete, Salvatore
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (04) : 499 - 505
[15] Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
Olivier Bouché
Meher Ben Abdelghani
Jean-Luc Labourey
Simon Triby
René-Jean Bensadoun
Thomas Jouary
Gaétan Des Guetz
World Journal of Gastroenterology, 2019, (29) : 4007 - 4018
[16] Panitumumab in the Treatment of Metastatic Colorectal CancerProfile Report
Sheridan M. Hoy
Antona J. Wagstaff
BioDrugs, 2007, 21 : 135 - 137
[17] Role of panitumumab in the management of metastatic colorectal cancer
Saif, Muhammad Wasif
Cohenuram, Michael
CLINICAL COLORECTAL CANCER, 2006, 6 (02) : 118 - 124
[18] Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
Tebbutt, Niall
Kotasek, Dusan
Burris, Howard A.
Schwartzberg, Lee S.
Hurwitz, Herbert
Stephenson, Joe
Warner, Douglas J.
Chen, Lisa
Hsu, Cheng-Pang
Goldstein, David
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 993 - 1004
[19] Capecitabine in combination with panitumumab is not the treatment of choice in older patients with metastatic colorectal cancer
Liposits, Gabor
Pfeiffer, Per
JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (01) : 114 - 115
[20] Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
Niall Tebbutt
Dusan Kotasek
Howard A. Burris
Lee S. Schwartzberg
Herbert Hurwitz
Joe Stephenson
Douglas J. Warner
Lisa Chen
Cheng-Pang Hsu
David Goldstein
Cancer Chemotherapy and Pharmacology, 2015, 75 : 993 - 1004

← 1 2 3 4 5 →